Pregnancy outcome after TNF‐α inhibitor therapy during the first trimester: a prospective multicentre cohort study
- 28 May 2015
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 80 (4), 727-739
- https://doi.org/10.1111/bcp.12642
Abstract
TNF-α inhibitors are considered relatively safe in pregnancy but experience is still limited. The aim of this study was to evaluate the risk of major birth defects, spontaneous abortion, preterm birth and reduced birth weight after first trimester exposure to TNF-α inhibitors. Pregnancy outcomes of women on adalimumab, infliximab, etanercept, certolizumab pegol or golimumab were evaluated in a prospective observational cohort study and compared with outcomes of a non-exposed random sample. The samples were drawn from pregnancies identified by institutes collaborating in the European Network of Teratology Information Services. In total, 495 exposed and 1532 comparison pregnancies were contributed from nine countries. The risk of major birth defects was increased in the exposed (5.0%) compared with the non-exposed group (1.5%; adjusted odds ratio (ORadj ) 2.2, 95% CI 1.0, 4.8). The risk of preterm birth was increased (17.6%; ORadj 1.69, 95% CI 1.1, 2.5), but not the risk of spontaneous abortion (16.2%; adjusted hazard ratio [HRadj ] 1.06, 95% CI 0.7, 1.7). Birth weights adjusted for gestational age and sex were significantly lower in the exposed group compared to the non-exposed cohort (P = 0.02). As a diseased comparison group was not possible to ascertain, the influence of disease and treatment on birth weight and preterm birth could not be differentiated. TNF-α inhibitors may carry a risk of adverse pregnancy outcome of moderate clinical relevance. Considering the impact of insufficiently controlled autoimmune disease on the mother and the unborn child, TNF-α inhibitors may nevertheless be a treatment option in women with severe disease refractory to established immunomodulatory drugs.Keywords
Funding Information
- Bundesministerium für Gesundheit (German Health Ministry
This publication has 45 references indexed in Scilit:
- Safety of TNF-α inhibitors during IBD pregnancy: a systematic reviewBMC Medicine, 2013
- Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2013
- High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancyAlimentary Pharmacology & Therapeutics, 2011
- Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics RegisterAnnals Of The Rheumatic Diseases, 2011
- VACTERL/VATER AssociationOrphanet Journal of Rare Diseases, 2011
- Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeedingRheumatology, 2010
- Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: Results of a national prospective studyArthritis & Rheumatism, 2009
- Do Tumor Necrosis Factor Inhibitors Cause Malformations in Humans?The Journal of Rheumatology, 2009
- A Safety Assessment of Tumor Necrosis Factor Antagonists During Pregnancy: A Review of the Food and Drug Administration DatabaseThe Journal of Rheumatology, 2009
- Statistical methods for estimating the probability of spontaneous abortion in observational studies—Analyzing pregnancies exposed to coumarin derivativesReproductive Toxicology, 2008